30-day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis

Trial Profile

30-day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Pulmonary embolism; Thromboembolism; Venous thrombosis
  • Focus Adverse reactions
  • Acronyms EINSTEINJunior
  • Sponsors Bayer
  • Most Recent Events

    • 13 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 12 Oct 2016 This trial was completed in Germany (end date: 2016-09-01).
    • 31 Aug 2016 This trial has been completed in Austria as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top